Wells Fargo has initiated coverage on Guardant Health Inc (GH), assigning the company an Overweight rating as of September 21, 2025. This marks the firm’s first assessment of Guardant Health, reflecting its evaluation of the company's business, industry dynamics, and growth prospects.
Headquartered in Palo Alto, California, Guardant Health is a precision oncology company that specializes in cancer treatment through proprietary blood-based tests and advanced analytics. With a market capitalization of $12.1 billion, the company continues to innovate in cancer diagnostics, offering tests such as the Guardant360 laboratory developed test and the Guardant360 CDx test, which provide vital insights for treatment decisions.
Currently, Guardant Health Inc has a trailing twelve months (TTM) earnings per share (EPS) of -3.21. The company’s upcoming earnings reports are scheduled for April 28, 2026, and July 28, 2026, with estimated EPS of -0.79 and -0.74, respectively.
Analyst ratings serve as professional opinions based on extensive research and financial models. While they can provide valuable insights, these assessments are based on assumptions that may not always hold true. Investors should consider a range of factors, including company fundamentals and industry trends, when making decisions. Analyst views should complement, rather than dictate, investment strategies.
It is also important to note that analyst ratings can evolve over time as new information becomes available. As of November 1, 2025, the consensus among analysts on Guardant Health is a Buy, with 13 Strong Buy, 17 Buy, and 3 Hold ratings recorded in recent evaluations.